Evaluation of the combination of daptomycin and nafcillin against vancomycin-intermediate Staphylococcus aureus | Zendy

Steve N. Leonard | Zendy; Kiri Rolek | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Evaluation of the combination of daptomycin and nafcillin against vancomycin-intermediate Staphylococcus aureus

Author(s) -

Steve N. Leonard,

Kiri Rolek

Publication year - 2012

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dks453

Subject(s) - daptomycin , nafcillin , staphylococcus aureus , vancomycin , microbiology and biotechnology , cephalosporin , methicillin resistant staphylococcus aureus , medicine , antibacterial agent , broth microdilution , antibiotics , minimum inhibitory concentration , pharmacology , chemistry , penicillin , biology , bacteria , genetics

Continued selective pressure from glycopeptide use has led to non-susceptible strains of Staphylococcus aureus, including vancomycin-intermediate S. aureus (VISA). Though relatively uncommon, VISA presents a particularly difficult clinical challenge when it arises. Pertinent to this investigation is the correlation between vancomycin intermediacy and daptomycin non-susceptibility. The aim of this study was to evaluate the potential for synergy between daptomycin and nafcillin against VISA.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research